ftInvstr
ALPA · Healthcare ₹62.05 -1.97% Mkt Cap ₹131 Cr

ALPA

Healthcare Drug Manufacturers - Specialty & Generic
₹62.05
-1.97% today · 30d -10.75%
as of 2026-09-04
Price · Daily Candles
“ALPA's operating profit jumps 28.71% in Q4 amidst revenue decline, but FIIs pare holdings.”
ALPA recorded a +28.71% YoY increase in operating profit for Q4 2026, reaching ₹3 Cr, despite a -21.35% YoY decline in revenue to ₹31 Cr for the same period. The stock trades at a TTM PE of 9.54, significantly below its sector average, while exhibiting a low risk profile (score of 90).
BULL CASE
+Operating profit saw a strong YoY increase of 28.71% in Q4 2026, reaching ₹3 Cr.
+The company's TTM PE ratio stands at 9.54, making it considerably cheaper than peers like SUNPHARMA (PE 38.57) and DIVISLAB (PE 80.99).
+ALPA's annual net profit CAGR over 5 years is 14.29%, indicating long-term profit growth.
+The stock is trading 34.35% off its 52-week high of ₹105.9, potentially offering an entry point.
BEAR CASE
Revenue declined significantly by -21.35% YoY in Q4 2026, and annual revenue also dropped -5.91% YoY in FY26.
Net profit saw a substantial annual decline of -27.57% YoY in FY26, reaching ₹14 Cr.
FII shareholding decreased by 0.03% QoQ to 0.35% in Q1 2027.
The stock has delivered a -32.93% return over the past year, underperforming the broader market.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹24 Cr
+25.22% YoY
NET PROFIT
₹1 Cr
-91.67% YoY
OPM
6.1%
-33.73pp YoY
EPS
₹0.49
PE 9.54
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-49.8%, h2=-50.0%, h3=-50.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
ALPA's TTM PE of 9.54 is significantly lower than sector peers like SUNPHARMA (38.57) and DIVISLAB (80.99), though its ROCE of 16.0% trails behind the best in class like LUPIN (34.06%).
PEERPEROCE %
ALPA9.5416.0
SUNPHARMA38.5721.44
DIVISLAB80.9921.56
CIPLA35.4518.37
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
52
SCORE / 100
Overall
6-axis composite of the sections below.
Performance UNDERPERFORMER 5
Valuation CHEAP 90
Growth DECLINING 26
Profitability DECENT 55
Technicals WEAK 47
Risk LOW 90
Key Stats
TTM PE
9.54
P/B
2.11
52W HIGH
₹101.0
OFF HIGH
-38.56%
MKT CAP
₹131 Cr
◉ Active Signals
MACDNeutral0.1119
RSI(14)Neutral40.7
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold ALPA and at what entry.

Sign up freeSign in